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A B S T R A C T
Purpose: The status of the local and circulating SOX9, a master regulator of the tumor fate, and its relevance to
tumor types, severity, invasion feature, response to therapy, and chemotherapy treatment were surveyed in bone
cancer in the current study.
Methods: The SOX9 expression level was evaluated in tissue and peripheral blood mononuclear cells from pa-
tients with different types of malignant and benign bone tumors also tumor margin tissues using Real-Time PCR.
The protein level of SOX9 was assessed using immunohistochemistry and western blot analysis. Also, the cor-
relations of the SOX9 expression level with the patient’s clinical and pathological features were considered.
Results: The remarkable overexpression of SOX9 was detected in bone tumors compared to tumor margin tissues
(P < 0.0001). Malignant bone tumors revealed a higher expression of SOX9 compared to benign tumors
(P < 0.0001) while osteosarcoma tumors showed higher expression levels compared to Ewing sarcoma, and
chondrosarcoma. Overexpression of SOX9 was observed in high grade, metastatic, recurrent tumors also tumors
with poor response to therapy. Besides, the patients under the chemotherapy treatment demonstrated higher
levels of SOX9 compared to the rest of malignant tumors (P = 0.02). The simultaneous up-regulation of cir-
culating SOX9 in the patients with bone cancer was observed compared to healthy individuals (P < 0.0001)
accompanying with overexpression of SOX9 in malignant tumors compared to benign tumors (P < 0.0001). The
circulating SOX9 expression was up-regulated in the patients with malignant bone tumors who receive che-
motherapy treatment also patients with high grade, metastatic, recurrent tumors. The protein level of SOX9 was
in line with our data on the SOX9 gene expression.
Conclusion: The simultaneous overexpression of local and circulating SOX9 in bone cancer besides its positive
correlation with tumor severity, malignancy, size, and chemotherapy may deserve receiving more attention in
bone cancer diagnosis and therapy.
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Bone tumors cover a wide range of clinical conditions, which im-
pose a burden of morbidity on the patients [1]. The uncontrolled pro-
liferation of bone cells might emerge from the existence of multipotent
stem cells (MSC) and they can cause bone tumor progression leading to
bone fracture, healthy bone tissue destruction, skeletal complications,
pain, and peripheral inflammation [2]. Also, various histological types
of bone tumors make them challenging to be handled by clinicians, so
they lead to remarkable failure in tumor removal and management
[2,3]. Recently, thanks to the improvements in imaging methods, en-
doscopic techniques, immune-based assays, gene analysis, surgical ap-
proaches, and new tumor markers detection; early tumor identification
is facilitated [4–6]. However, the necessity of early diagnosis and tumor
screening, as well as the unknown cause of bone cell dis-regulation and
aberrant proliferation, provoked researchers to characterize the mole-
cular mechanisms underlying the bone tumor initiation and progression
[7–10]. SOX9 (SRY-box transcription factor 9) is proposed as a novel
cancer stem cell (CSCs) marker with the ability in maintaining cells in
the undifferentiated status, which causes their re-newel and differ-
entiation [11,12]. Moreover, SOX9 is a multi-functional transcription
factor, which plays a critical role in maintaining stem cell features, cell
growth, and differentiation [13]. The effective role of SOX9 in tissue
organogenesis like chondrogenesis might be due to its correlation with
the downstream signaling pathways like Wnt and Notch, which spotted
SOX9 as a potent biomarker affecting tumor cell fate [14–16]. The
SOX9 tendency to be elevated during tumor genesis has been reported
in some malignancies such as esophageal, prostate, and pancreatic
cancers [17,18]. Interestingly, it was shown that the cartilage formation
was enhanced following the simultaneous delivery of morphogenetic
protein 2, which is considered as a regulator of osteogenesis and
chondrogenesis and SOX9 expression in dedifferentiated chondrocytes
[19]. Also, it was shown that SOX9 can regulate the collagen tran-
scription level in response to the 17β-estradiol, and cause chon-
drogenesis [20,14,21]. Despite evidence on the effective role of SOX9,
as a regulator in chondrogenesis and collagen expression [22], the re-
levance of SOX9 in bone tumor genesis has yet to be clarified. Re-
garding the potent role of SOX9 in tissue regeneration and organo-
genesis, and also its correlation with cellular signaling pathways
affecting cell growth, proliferation, and death; the current study aimed
to evaluate the status of SOX9 in diverse bone tumor and healthy bone
tissues at both gene and protein levels beside assessing the statement of
SOX9 in peripheral blood mononuclear cells of the patients with various
types of bone tumors, to provide evidence regarding the status of local
and circulating SOX9 in bone cancer.
2. Material and method
2.1. Patients and sample collection
The number of 150 bone tumor tissues, 150 tumor margins, and 150
blood samples of the same patients with bone tumor as well as 60
healthy blood samples were enrolled in the current study with local
ethical approval and informed consent. The project was approved
ethically by the ethics committee of vice president of research at Iran
University of Medical Sciences (IR.IUMS.REC.1397.1283). The tumor
and tumor margin samples were collected from patients who were
subjected to surgery at the Shafa Orthopedic Hospital. Following sur-
gical resection, fresh tissues were kept at −80 for later evaluation. To
evaluate the circulating SOX9 gene expression level, the total amount of
6 ml peripheral blood was taken from the patients and healthy age and
sex-matched controls and applied for the peripheral blood mononuclear
cell (PBMC) separation. The clinic- pathological features of the patients
with malignant bone tumors are summarized in Table 1 and the vari-
ables are presented as the number of patients and percentages. Also, the
statistical differences between malignant bone tumors and the variables
are shown in Table 1. Briefly, the equal number of most prevalent types
of malignant bone tumors including osteosarcoma, Ewing's Sarcoma,
and chondrosarcoma were enrolled in the study. As it is shown in
Table 1, 44% of patients with osteosarcoma and 56% of patients with
Ewing's Sarcoma were under 20 years of age while all of the chon-
drosarcoma patients were above 20. In this survey, 48%, 32%, and 40%
of the patients were male in osteosarcoma, Ewing's Sarcoma, and
chondrosarcoma, subsequently.
Additionally, 85%, 75%, and 42.85% of the patients had high-grade
tumors in osteosarcoma, Ewing's Sarcoma, and chondrosarcoma, sub-
sequently. Also, the tumor size in 75%, 55%, and 38.1% of the patients
was over 8 cm in osteosarcoma, Ewing's Sarcoma, and chondrosarcoma,
subsequently. As a matter of invasive feature of tumors, 36% of os-
teosarcoma, 36% of Ewing's Sarcoma, and 28% of chondrosarcoma
tumors were metastatic. Moreover, amongst patients with malignant
bone tumors, 68% of patients with osteosarcoma and 56% of patients
with Ewing's Sarcoma received chemotherapy treatment before the
surgery and none of our patients with osteochondroma were under
chemotherapy regimen prior to the surgery. The osteosarcoma patients
received the standard combination of doxorubicin, cisplatin, and
methotrexate as chemotherapy approaches while Ewing's Sarcoma pa-
tients received the combination of vincristine, cyclophosphamide, and
doxorubicin. The tumor necrosis over 95% was used as a cutoff value to
determine the histological response to the chemotherapy treatment
based on the Huvos system grading. Accordingly, grade 1/2 shows little
or partial response to the chemotherapy (low rate of tumor necrosis)
while grade 3/4 shows good response to the chemotherapy (over 95%
tumor necrosis) [23]. In the current study, 66.66% of patients with
osteosarcoma and 64.28% of patients with Ewing's Sarcoma showed
poor response to chemotherapy treatment. Moreover, 28% of osteo-
sarcoma tumors and 24% of Ewing's Sarcoma tumors were recurrent.
Moreover, the clinical features of patients with benign bone tumors are
summarized in Table 2. Among the 75 patients with benign bone tu-
mors, 28% of patients with osteochondroma, 36% of patients with
Giant-cell tumor and 52% of patients with exostosis were under
20 years of age. Among the enrolled patients with benign bone tumors,
76% of osteochondroma, 76% of Giant cell Tumor, and 64% of exostosis
patients were male. As it is indicated in Table 2, most of the patients
had tumors less than 8 cm in size. Additionally, the biochemical fea-
tures of the patients are summarized in Table3, which shows over 80%
of the patients were normal as a point of FBS, SGPT, SGOT, LDL, WBC,
and HB, also approximately around 70% of the patients were at the
normal range of RBC, CPP, and ESR
2.2. Peripheral blood mononuclear cell (PBMC) separation
The density gradient centrifugation by Ficoll-Hypaque (Sigma
Chemical Co, St Louis, MO, USA) was applied for PBMC separation from
the collected blood of patients and healthy subjects. Following se-
paration, cells were washed and purified using phosphate-buffered
saline (PBS) and counted by hemocytometer and the same number of
cells was used for further evaluation.
2.3. RNA extraction, cDNA synthesis, and Real-Time PCR
To measure the gene expression level of SOX9, the tumor and tumor
margin tissues, as well as PBMCs, were used for RNA extraction by
Trizol (Invitrogen, Grand Island, USA) based on the manufacturer’s
instructions. The quantity and quality of the extracted RNA of each
sample were evaluated using a Nanodrop spectrophotometer
(Nanodrop Technologies). The amount of 1 µg of extracted RNA was
applied for cDNA synthesis using PrimeScript First Strand cDNA
Synthesis Kit Takara, Japan) according to the manufacturer’s instruc-
tions. The synthesized cDNA of each sample was used for Real-Time
PCR reaction using SYBR Premix Ex Taq II (Takara, Japan) which was
performed in Applied Biosystems Step One Plus, Real-time system
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(Applied Biosystems, USA). The designed primers which were used are
listed in Table 4 and the running program was as 1 cycle at 95 °C for
5 min following 40 cycles at 95 °C for 5 s, 55 °C for 20 s, and 60 °C for
35 s. To normalize the SOX9 gene expression, the beta-actin expression
level was assessed as a housekeeping gene and the comparative CT
(2−ΔCt) method was applied for analysis.
2.4. Immunohistochemistry
To evaluate the protein expression level of SOX9 in tumor and
normal tissues, samples were evaluated via immunohistochemistry.
Briefly, following tissue fixation in 4% paraformaldehyde and incuba-
tion in 20% sucrose, the frozen tissue blocks were prepared using
Optimal Cutting Temperature (OCT) embedding medium during in-
cubation in −27 °C. The 10 nm tissue sections of samples were pre-
pared using cryotome and the washing buffer, H2O2 solution, Triton
5%, and blocking buffer were used subsequently prior to antibody
staining. The dilution of 1:400 of a monoclonal antibody of SOX9 (Cell
Signaling, the Netherlands) was applied following proper incubation
and the anti-rabbit IgG HRP-conjugated secondary antibody (Cell
Signaling, the Netherlands) was used with 3, 3′-diaminobenzidine
(DAB, Dako) in an appropriate incubating time to visualize the antibody
binding. The ethanol and xylolin were used for final-dehydration and
subsequent mounting. The semi-quantitative method was applied for
slide scoring by pathologists and based on the staining intensity the
scores were assigned as 0 (absent), +1 (weak), +2 (moderate), or +3
(strong) staining.
Table 1
The clinic- pathological features of patients with malignant bone tumors.

















































































* Indicated the number of patients with available information.
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* Indicated the number of patients with available information.
Table 3
The biochemical features of patients with bone tumors.



































































































Primers used for qRT-PCR assessment of gene expressions.








5-GAT CTC CTT CTG CAT CCT GT-3′
5′-TGG GCA TCC ACG AAA CTA C- 3′
57
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2.5. Protein extraction and western blot analysis
The western blot analysis was applied to further evaluate the status
of the SOX9 protein level in tumor and normal bone tissues. In this
regard, the approximate amount of 5 mg of tissue powder was added to
the lysis buffer mixture containing Phosphatase Inhibitor, Protease
Inhibitor, and phenylmethylsulfonyl fluoride (PMSF). Following proper
vortex, ice incubation, and centrifugation, the supernatants were sub-
jected to protein concentration assay separately using BCA Protein
Assay Kit (TaKaRa Bio Inc, Japan). Notably, the bovine serum albumin
was applied as the standard. The 12% SDS-polyacrylamide gel elec-
trophoresis was used for total protein separation by transferring to
polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA,
USA). The Tris-buffered Saline containing 5% skim milk and 0.1%
Tween 20 were utilized for membrane blockage for 4 h at room tem-
perature. The membranes were incubated overnight with SOX9 (Cell
Signaling, the Netherlands) and GAPDH (Cell Signaling, the
Netherlands) primary antibodies at 4 °C following incubation at room
temperature with HRP-conjugated secondary antibody. The Amersham
ECL detection reagent (Amersham Biosciences, UK) was used for the
immunodetection of the proteins. To quantify the protein level, the
intensity of each protein bands was measured from the scanned film by
densitometric analysis using Image J software (NIH, Bethesda, MD,
USA) [24]. The ratio of the SOX9 protein level to the GAPDH intensity
was reported as a final result of protein quantification for each patient.
2.6. Statistical analysis
The comparative CT (2−ΔCt) method was used for gene expression
analysis and the differences between groups were assessed statistically
using the t-test and one-way analysis of variance (ANOVA). Based on
the Kolmogorov-Smirnov analysis, data in benign and malignant groups
distributed normally. The correlation of SOX9 expression level with the
age, tumor size, tissue gene expression, PBMC gene expression, and
protein level was assessed using the Pearson correlation coefficient test.
The chi-square test was used to analyze the statistical differences be-
tween bone tumors and the variables (age, gender, tumor grade, tumor
size, metastasis, chemotherapy status, response to therapy and tumor
recurrence). The regression analysis was applied to determine the value
of the variables in predicting SOX9 expression level in tumors. The
Graph Pad Prism version 6 (Graph Pad Software, San Diego California)
and Statistical Package for Social Science (SPSS v.16) were used for
calculation of all statistics. P values< 0.05 (two-sided) were con-
sidered statistically significant.
3. Results
3.1. The SOX9 expression level in different types of primary bone tumors
Based on our data, the expression level of SOX9 was elevated sig-
nificantly in bone tumors compared to normal bone tissues
(P < 0.0001) (Fig. 1a). The mean and standard error mean (SEM) of
SOX9 mRNA level was 2.973 ± 0.1005 and 0.1858 ± 0.02 in tumor
and margin groups, respectively which reveals the remarkable elevation
of SOX9 expression in tumor tissues. Moreover, regarding the possible
involvement of SOX9 in tumor severity, the expression level of SOX9
was detected in malignant and benign bone tumors separately and it
was revealed that SOX9 expression was increased significantly in ma-
lignant bone tumors (P= 0.0001) compared to benign tumors (Fig. 1b).
Among the malignant tumors, the osteosarcoma, Ewing's Sarcoma, and
chondrosarcoma tumor tissues were included in the survey and our data
showed considerable overexpression of SOX9 in each malignant tumor
group compared to their matched normal margins (P = 0.0001). Ac-
cordingly, the mean and the SEM of the SOX9 mRNA level were
4.29 ± 0.22, 3.56 ± 0.29, and 3.63 ± 021 in osteosarcoma,
chondrosarcoma, and Ewing’s Sarcoma, respectively (Fig. 1c). The
approximate 1.20- and a 1.18-fold increase was observed in the SOX9
expression level in osteosarcoma compared to chondrosarcoma and
Ewing’s Sarcoma, respectively. Despite the overexpression of SOX9 in
benign bone tumors (osteochondroma, Giant cell Tumor, and exostosis)
compared to each group-matched normal margin (P = 0.0001), no
difference in the expression level of SOX9 was observed between benign
tumor groups (Fig. 1d). The SOX9 mRNA level was 4.59 ± 0.15 and
3.75 ± 0.39 in tumor tissue of osteosarcoma and Ewing’s Sarcoma of
patients received chemotherapy regimen, respectively, which revealed
the approximate of 1.22- and 1.32-fold increase compared to the pa-
tients with no history of chemotherapy in each group (Fig. 1e). Notably,
high-grade tumors referred to those tumors in which their cells are
moderate or poorly differentiated compared to healthy bone cells. Ac-
cordingly, the mean mRNA level of SOX9 in high-grade tumors of os-
teosarcoma, chondrosarcoma and Ewing’s Sarcoma was 4.70 ± 0.17,
4.47 ± 0.41 and 4.26 ± 0.21, respectively, which showed 1.37, 1.46-
and a 1.58-fold increase compared to the low-grade tumors in each
group, respectively (Fig. 1f). The significant overexpression of SOX9
was detected in metastatic tumors of osteosarcoma (5.21 ± 0.18),
chondrosarcoma (4.68 ± 051), and Ewing’s Sarcoma (4.36 ± 0.30)
which showed 1.38, 1.49- and a 1.35-fold increase compared to non-
metastatic tumors in each group, respectively (Fig. 1g). Based on our
data, osteosarcoma tumors with poor response to chemotherapy ex-
pressed a higher level of SOX9 (4.85 ± 0.19) compared to tumors with
good response (4.13 ± 0.13) (P = 0.02), also Ewing’s Sarcoma tumors
with poor response to chemotherapy expressed 4.62 ± 0.21 mRNA
level of SOX9 compared to tumors with good response (3.5 ± 0.49)
which was statistically significant (P = 0.04) (Fig. 1h). The over-
expression of SOX9 was observed in recurrent osteosarcoma tumors
(4.78 ± 0.28) and recurrent Ewing’s Sarcoma (4.92 ± 0.23) com-
pared to the non-recurrent tumors (4.92 ± 0.23) (Fig. 1i)
3.2. The circulating level of SOX9 expression in patients with bone tumors
Considering the feasibility and preference of circulating biomarkers
in efficient and early diagnosis, the expression pattern of SOX9 was
evaluated in peripheral blood of patients with bone cancer. Based on
our data, the expression level of SOX9 was significantly elevated in the
PBMC of patients with a bone tumor compared to healthy controls
(P = 0.0001) (Fig. 2a). It was revealed that the mean and SEM of the
SOX9 mRNA level was 0.519 ± 0.02 and 0.03 ± 0.0043 in patients
compared to controls. Apparently, the mRNA level of SOX9 was re-
duced in peripheral blood of patients compared to their tumor tissues
however its up-regulation was considerable in patients in comparison to
healthy subjects. Additionally, the expression level of SOX9 was en-
hanced in patients with malignant bone tumors compared to patients
with benign bone tumors (P = 0.0001) (Fig. 2b) with the SOX9 mRNA
level mean and SEM of 0.694 ± 0.025 and 0.34 ± 0.01, respectively.
The PBMC of malignant bone tumors showed significant elevation in
SOX9 expression level compared to the PBMC of healthy controls
(P = 0.0001) and the SOX9 level was significantly overexpressed in
patients with osteosarcoma (0.78 ± 0.05) compared to patients with
chondrosarcoma (0.61 ± 0.06) (Fig. 2c). In accordance with tumor
tissues, the PBMC of benign bone cancers showed no statistical differ-
ence between osteochondroma, Giant cell Tumor, and 64% exostosis
while considerable expression of SOX9 was observed in benign bone
cancers compared to the PBMC of healthy subjects (P = 0.0001)
(Fig. 2d). The mRNA level of SOX9 in PBMC of patients with osteo-
sarcoma who received chemotherapy regimen was 0.84 ± 0.004
compared to the patients with no history of chemotherapy
(0.63 ± 0.06) which showed 1.33 fold increase in SOX9 mRNA level
(P = 0.014) while the difference was not significant for Ewing’s Sar-
coma (Fig. 2e). Based on our data, the circulating level of SOX9 was
increased in osteosarcoma patients with high-grade tumors
(0.85 ± 0.04) (P = 0.005), in chondrosarcoma patients
(0.74 ± 0.10) (P = 0.02) and patients with Ewing’s Sarcoma
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(0.77 ± 0.04) (P = 0.02) (Fig. 2f). The mRNA level of SOX9 in PBMC
of the patients with metastatic osteosarcoma (0.92 ± 0.06), chon-
drosarcoma (0.81 ± 0.11) and Ewing’s Sarcoma (0.82 ± 0.05)
showed significant elevation compared to nonmetastatic groups
(Fig. 2g) while the SOX9 level revealed no significant difference in
malignant bone cancers with poor or good response (Fig. 2h). Notably,
the PBMC of the patients with recurrent osteosarcoma showed sig-
nificant overexpression of SOX9 compared to the rest of osteosarcoma
patients (P = 0.02) while Ewing’s Sarcoma patients revealed no dif-
ference in SOX9 expression level in recurrent versus non-recurrent tu-
mors (Fig. 2I).
3.3. The overexpression of SOX9 protein in bone tumor tissues
According to delineate the expression pattern of SOX9 in bone tu-
mors, it is critical to determine that the overexpression of SOX9 in
Fig. 1. The SOX9 mRNA expression in bone tumors. The SOX9 expression level was evaluated in different bone tumor tissues and its expression level was elevated in
a bone tumor (a) versus normal bone tissues also malignant bone tumors versus benign tumors (b). The SOX9 expression evaluated in different types of malignant
bone tumors compared to tumor margins in each group (c) and benign bone tumors normal paired tissue in each group (d). SOX9 overexpression observed in
chemotherapy received patients (e), high-grade tumors (f), metastatic tumors in each malignant group (g), tumors with poor response to chemotherapy (h), and
recurrent tumors (i). The Statistical differences between groups are shown as asterisk (*= P < 0.05, **= P < 0.01, ***= P < 0.001, ****= P < 0.0001).
A. Hosseini, et al. Journal of Bone Oncology 23 (2020) 100300
5
tumor tissues is accompanied by an elevation of its protein level. To this
aim, the protein level of SOX9 was assessed in tumor and normal tissues
using immunohistochemistry to determine both localization and ex-
pression levels of SOX9. Based on our data, 12% of osteosarcoma tu-
mors showed no expression of SOX9 while 16%, 32%, and 40% of os-
teosarcoma tumors revealed a weak, moderate, and strong level of
SOX9, respectively (Table 5). Also, 20%, 28%, and 28% of Ewing's
Sarcoma tumors showed a weak, moderate, and strong level of SOX9,
respectively while 24% of these tumors had no expression. The
representative images of SOX9 immunohistochemistry staining in bone
tumors are illustrated in Fig. 3. Based on our data, 40% of chon-
drosarcoma tumors showed weak expression while 20% and 16% of
tumors showed moderate and strong SOX9 expression, respectively.
Also, 40% of the patients with the history of chemotherapy regimen
showed moderate expression of SOX9 while 23% of patients revealed
no expression. The strong expression of SOX9 was not observed in be-
nign bone cancers while 36%, 20%, and 24% of osteochondroma, Giant
cell Tumor, and exostosis tumors showed a moderate level of SOX9,
Fig. 2. The SOX9 expression in peripheral blood of patients and healthy subjects. The expression level of SOX9 was increased in PBMCs of patients with bone cancer
compared to healthy subjects (a) also patients with malignant bone tumors compared to benign tumors (b). The overexpression of SOX9 is shown in different types of
malignant bone tumors compared to healthy subjects (c), also different types of benign bone tumors (d), SOX9 expression elevated in osteosarcoma patients receiving
chemotherapy regimen (e), also the SOX9 overexpression observed in malignant high-grade tumors (f) and malignant metastatic tumors in each group (g). The SOX9
expression in PBMC showed no difference in patients with poor or good response to therapy (h), patients with recurrent tumors overexpressed circulating SOX9 (i).
The Statistical differences between groups are shown as (*= P < 0.05, **= P < 0.01, ****= P < 0.0001).
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respectively. Moreover, the approximate of 70.83% of metastatic tu-
mors showed a strong expression of SOX9. Additionally, the SOX9
protein evaluation was detected via western blot analysis to clarify the
amount and total SOX9 protein expression in tissues. The western blot
analysis was performed on 29 malignant tumors (10 osteosarcoma, 9
Giant-cell Tumor, 10 chondrosarcomas), 26 benign tumors (9 Giant-cell
Tumor, 9 osteochondroma, 8 exostosis) and 20 margin tissues and the
representative of the protein bands are illustrated in Fig. 4a. Our data
revealed that malignant tumors significantly overexpress SOX9 protein
compared to tumor margins (P = 0.04) (Fig. 4b). The up-regulation of
SOX9 was detected in malignant tumors compared to benign tumors
although it was not statistically significant. Based on our data, the ex-
pression of SOX9 in benign bone tumors was not remarkable compared
to normal bone tissues (Fig. 4b).
Table 5
The immunohistochemistry results of Sox-9 protein evaluation in patients with bone cancer.
Scores Osteosarcoma Ewing's Sarcoma Chondrosarcoma Chemotherapy received patients
Negative 12% 24% 24% 23%
Positive (1+) 16% 20% 40% 16%
Positive (2+) 32% 28% 20% 40%
Positive (3+) 40% 28% 16% 21%
Scores Osteochondroma Giant cell Tumor Exostosis Metastatic patients
Negative 48% 60% 56% 0
Positive (1+) 16% 20% 20% 4.16%
Positive (2+) 36% 20% 24% 25%
Positive (3+) 0 0 0 70.83%
Fig. 3. The SOX9 protein assessment via immunohistochemistry. The SOX9 protein level was evaluated in different bone tumor tissues and the SOX9 expression level
was indicated as weak expression (a), moderate expression (b), and strong expression (c).
Fig. 4. The total SOX9 protein level enhanced in malignant bone tumors. The protein level of SOX9 was measured in malignant and benign bone tumors also non-
cancerous bone tissues. The overexpression of SOX9 protein was detected in malignant bone tumors (a). The relative SOX9 level of expression was significantly
elevated in malignant tumors compared to normal tissues (b). The SOX9 protein size was 70 KD which was normalized with internal control GAPDH (35KD).
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3.4. Association of SOX9 expression with the demographic features of the
bone cancer patients
As it is illustrated in Table 6, in malignant bone cancers, the SOX9
expression in tumor tissues and SOX9 protein levels by im-
munohistochemistry showed a significant correlation with the patient's
age while SOX9 expression in PBMC was not correlated with age. In
malignant bone cancers, the SOX9 gene expression in tumor tissues,
PBMC, and its protein level was correlated with tumor size, sig-
nificantly. Also, in malignant bone cancers, the SOX9 expression in
tumor tissue of the patients was significantly correlated with the SOX9
level in PBMC and the SOX9 protein level of the same patients also the
SOX9 gene expression in PBMC of the patients was correlated with the
protein level of SOX9 in the same patients. In benign bone cancer, no
correlation of SOX9 expression in tumor tissue, PBMC, and protein level
with age was observed. However; the Sox-9 expression in benign bone
cancers was significantly correlated with tumor size in benign tumor
tissue, PBMC, and protein level. The same as malignant bone cancers,
SOX9 gene expression in tumor tissues of benign bone cancers was
correlated with its protein expression and expression in PBMC of the
same patients also SOX9 expression in PBMC of benign bone cancers
was correlated significantly with SOX9 protein level in the same pa-
tients (Table 6). The regression analysis of the common variables in
both benign and malignant bone cancers revealed that the tumor size
and the SOX9 expression level in PBMC of the patients also the protein
level of SOX9 in tumor tissues were significantly valuable in predicting
SOX9 expression level in tumor tissues. Also, the impact of tumor ma-
lignancy on the SOX9 gene expression level in tumor tissue was con-
siderable and nearly significant (P = 0.051) (Table 7).
4. Discussion
Despite recent improvements regarding primary bone tumor
diagnosis and therapeutic strategies, nonspecific symptoms beside late
patient referring and early detection failing are still prominent draw-
backs causing cancer-induced morbidity and mortality [2,25]. More
recently, SOX9 gained attention, as a multi-functional transcription
factor, by considering its role in regulating cell growth, development,
and differentiation, which might lead to tissue organogenesis and tissue
direction to specific lineage [11,18]. Considering the pushing role of
SOX9 in tumor formation and development, in the current study, its
local and circulating expression pattern was perused in different types
of bone tumors. The SOX9 gene overexpression level was detected in
bone tumors compared to normal paired bone tissues. In line with our
data, the up-regulation of SOX9 was reported in other malignancies
such as esophageal, prostate, and pancreatic cancers [17,18,21]. In-
terestingly, the SOX9 overexpression was observed in bone malignant
tumors compared to benign bone tumors. In accordance with our data,
it was demonstrated that SOX9 expression increased in osteosarcoma
tissues at both protein and gene levels, which was correlated with
tumor advance stage and invasive features [26]. In support of this
evidence, our data revealed that the SOX9 overexpression in malignant
bone tumors was correlated with tumor size, high grade, invasive fea-
ture, tumor recurrence, and poor response. Interestingly, no previous
study provided evidence on the status of SOX9 in different types of bone
tumors. To clarify whether the SOX9 expression pattern might be af-
fected by tumor type; the tumor tissues of the most prevalent malignant
(osteosarcoma, Ewing sarcoma, and chondrosarcoma), as well as the
most prevalent benign (Exostosis, Giant Cell tumor (GCT), and os-
teochondroma) bone tumors, were included in our survey, and based on
our data, despite SOX9 overexpression in tumors tissues, no specific
differences were observed regarding SOX9 expression in different types
of benign bone tumors both in tumor tissues and PBMCs of the patients.
Also, it was reported that SOX9 is involved in mesenchymal cells into
chondrocytes differentiation; therefore, it might have a distinguishable
expression in primitive small cell malignancies likewise mesenchymal
chondrosarcoma [27]. Our data revealed that among small cell malig-
nancies such as chondrosarcoma, Ewing sarcoma, and partly osteo-
sarcoma; the expression level of SOX9 has increased significantly
compared to normal bone tissues and benign bone tumors, while the
SOX9 expression was increased more in osteosarcoma compared to the
other malignant bone tumors. Based on our data, the SOX9 expression
level enhanced in local recurrent tumors as well as tumors with high
grades and metastatic tumors compared to the rest of malignant tumors,
which indicated the possible impact of SOX9 in tumor invasive beha-
vior. Tumor recurrence occurs due to the activation and/or re-activa-
tion of remaining tumor cells following a period of remission and stands
as a challenging concern for both treatment and diagnosis. Regarding
bone cancer, tumor recurrence might rate up to 65%, which is
Table 6
The correlation of Sox-9 expression with patient’s age, tumor size, gene expression level in tumor tissue, PBMC and protein expression level.
Variable Malignant bone cancer Benign bone cancer
Tumor gene expression PBMC gene expression Protein expression Tumor gene expression PBMC gene expression Protein expression
Age
Correlation 0.244* 0.128 0.237* −0.135 −0.083 −0.079
P value 0.035 0.274 0.041 0.249 0.480 0.502
Tumor size
Correlation 0.691** 0.640** 0.711** 0.678** 0.653** 0.623**
P value 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
Tumor gene expression
Correlation 0.834** 0.793** 0.814** 0.702**
P value 1 0.0001 0.0001 1 0.0001 0.0001
PBMC gene expression
Correlation 0.834** 0.717** 0.814** 0.866**
P value 0.0001 1 0.0001 0.0001 1 0.0001
*Correlation is significant at the 0.05 level (2-tailed).
**Correlation is significant at the 0.01 level (2-tailed).
Table 7
The regression model of Sox-9 tumor expression in patients with bone cancer.
Variable (predictors) Standardized Coefficients
(Beta)
t P value
Tumor type 0.083 1.209 0.229
Tumor malignancy 0.146 1.972 0.051*
Tumor size 0.137 2.553 0.012**
Patient age 0.049 1.382 0.170




Sox-9 protein level 0.201 3.288 0.001**
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considerable and also problematic for the patients, and determining the
underlying mechanism should be considered as a priority [28]. The
effective role of SOX9 in tumor severity was observed in other tissues.
Accordingly, it was shown that SOX9 was overexpressed in human
esophageal squamous cell cancer which was correlated with tumor se-
verity also SOX9 stimulated cell proliferation and tumorigenicity, pos-
sibly through affecting phosphorylated FOXO1, FOXO3, and Akt [21].
Our data compared the possible effects of chemotherapy treatment on
the expression of SOX9 and therefore revealed that SOX9 was over-
expressed in malignant tumor tissues of the patients under che-
motherapy regimen compared to those malignant tumors without
chemotherapy history. However; the overexpression of SOX9 in che-
motherapy-received patients was remarkable in tumor tissues not in
PBMCs. It was elucidated that tumor mass is a heterogeneous popula-
tion of cells composed of CSC subpopulation [29]. Several studies re-
ported that chemotherapy treatment is applied as a therapeutic choice
to shrink the tumor and destroy cancer cells that might lead to CSC
enrichment as well as inducing CSC activation and reconstruction
[30,31]. Interestingly, the promoting effect of chemotherapy on CSC
make-up and renewal might increase tumor cell capability of the divi-
sion [32]. Regarding the fact that SOX9 is considered as a CSC marker
and tumor mass composed of the CSC population, the higher SOX9
expression in bone tumor tissues is rational and explainable [11]. Ac-
cordingly, due to the effective role of SOX9, as a master regulator in
tumor fate, it might be considered as an effective or responsible factor
for tumor response to the treatments and can also be proposed for
further evaluations in chemotherapy agent design. A growing body of
evidence supports the efficiency of peripheral blood as a possible cir-
culating source of biomarkers to get insight into the less invasive di-
agnostic approaches [30,33]. The behavior of immune cells in patho-
logical conditions like cancer is influenced by tumor cells which cause
functional changes in immune cells and subsequent immune system
response towards tumor retrieval or proliferation [34]. Therefore,
cancer-related gene expression profiling of PBMCs might reflect the
presence of tumor cells/cancer stem cells in blood, and also uncover the
functional alteration of immune cells regarding tumor formation and
development. Up to the best of our knowledge, no previous study has
been performed to evaluate the simultaneous expression pattern of
SOX9 in blood and tumor tissues of various bone tumors. The SOX9
expression assessment in PBMCs of the patients revealed its over-
expression in patients with bone tumors compared to healthy subjects.
Also, the patients with malignant tumors expressed higher levels of
SOX9 compared to the rest of the patients, which indicates its possible
diagnostic value to distinguish bone cancer as a point of severity. The
expression level of circulating SOX9 showed significant elevation in
osteosarcoma patients compared to the other malignant tumors also
overexpression was observed in high grade, metastatic and recurrent
tumors in osteosarcoma, Ewing's Sarcoma and chondrosarcoma while
showed no considerable differences among different types of benign
bone tumors. Based on our data, it seems that local SOX9 might be more
effective on bone tumor diagnosis as well as tumor formation under-
lying mechanism. The lower level of SOX9 mRNA in peripheral blood
compared to local tumor tissue can be rationally influenced by the
number of undifferentiated cells and also cancer stem cells present in
tumors compared to blood [32]. Also, only a small fraction of the CSC
population might release into the bloodstream, which makes it difficult
for detection and evaluation [35]. Based on the fact that mRNA ex-
pression might be affected by several genetic and epigenetic factors,
mRNA expression might not always end up in the protein translation
[36]. Therefore, in the current study, the SOX9 assessment was eval-
uated at both mRNA and protein levels to present a more valuable and
relevant outcome. Based on our data, the SOX9 mRNA and protein
elucidated consistency and the simultaneous overexpression of SOX9 at
both mRNA and protein levels in bone tumors, and also malignant tu-
mors delineated a promising picture of SOX9 as a diagnostic marker in
bone cancer. Altogether, considering the simultaneous assessment of
SOX9 expression in tumor tissues beside PBMCs of the patients, our data
provide a more efficient and accessible picture of SOX9 expression
pattern in bone cancer and further pieces of evidence to utilize SOX9 as
a diagnostic marker; however, further mechanistic studies are required
to unravel the exact involvement of SOX9 in bone tumor pathogenesis.
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